• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

改善转移性HER阳性和HER低表达乳腺癌女性的治疗结局

Improving Outcomes for Women With Metastatic HER-Positive and HER-Low Breast Cancer.

作者信息

Graff Stephanie L, McGinn Christine, Showalter Jeanine R

机构信息

From Lifespan Cancer Institute, Providence, Rhode Island.

Legorreta Cancer Center, Brown University, Providence, Rhode Island.

出版信息

J Adv Pract Oncol. 2024 Apr;15(3):187-190. doi: 10.6004/jadpro.2024.15.3.6. Epub 2024 Apr 1.

DOI:10.6004/jadpro.2024.15.3.6
PMID:39297071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11406316/
Abstract

At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status, and evidence-based practices for managing adverse events associated with novel HER2 agents.

摘要

在2023年JADPRO直播活动中，演讲者们讨论了HER2阳性转移性乳腺癌临床实践的最新进展。在该环节中，他们回顾了美国食品药品监督管理局（FDA）近期的批准情况、HER2低表达状态的临床相关性，以及管理与新型HER2药物相关不良事件的循证实践。

相似文献

1
Improving Outcomes for Women With Metastatic HER-Positive and HER-Low Breast Cancer.改善转移性HER阳性和HER低表达乳腺癌女性的治疗结局
J Adv Pract Oncol. 2024 Apr;15(3):187-190. doi: 10.6004/jadpro.2024.15.3.6. Epub 2024 Apr 1.
2
Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer.改善HER2阳性转移性乳腺癌女性的治疗
J Adv Pract Oncol. 2023 Apr;14(3):248-251. doi: 10.6004/jadpro.2023.14.3.13. Epub 2023 Apr 1.
3
Advancing Precision-Targeted Treatment for Patients With Metastatic Non-Small Cell Lung Cancer.推进转移性非小细胞肺癌患者的精准靶向治疗。
J Adv Pract Oncol. 2024 Apr;15(3):170-176. doi: 10.6004/jadpro.2024.15.3.7. Epub 2024 Apr 1.
4
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.在PARP抑制剂时代优化HER2阴性转移性乳腺癌的管理——乳腺癌专家组会议纪要
Chin Clin Oncol. 2020 Oct;9(5):61. doi: 10.21037/cco-20-138. Epub 2020 Aug 17.
5
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management.人表皮生长因子受体2阳性乳腺癌的进展：新型疗法与不良事件管理
J Adv Pract Oncol. 2019 Mar;10(2):136-153. Epub 2019 Mar 1.
6
Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.新型 HER2 靶向治疗药物用于治疗 HER2 阳性转移性乳腺癌。
Cancer. 2020 Oct 1;126(19):4278-4288. doi: 10.1002/cncr.33102. Epub 2020 Jul 28.
7
Trastuzumab-containing regimens for metastatic breast cancer.用于转移性乳腺癌的含曲妥珠单抗方案。
Cochrane Database Syst Rev. 2014 Jun 12;2014(6):CD006242. doi: 10.1002/14651858.CD006242.pub2.
8
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC.更新转移性非小细胞肺癌患者的靶向治疗模式。
J Adv Pract Oncol. 2023 Apr;14(3):241-247. doi: 10.6004/jadpro.2023.14.3.12. Epub 2023 Apr 1.
9
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.人表皮生长因子受体2阳性转移性乳腺癌患者的当前治疗方法
Front Oncol. 2018 Apr 3;8:89. doi: 10.3389/fonc.2018.00089. eCollection 2018.
10
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.在 HER2 阳性乳腺癌中实施抗体药物偶联物 (ADC)：现状和未来方向。
Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y.

本文引用的文献

1
Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases.抗体药物偶联物与立体定向放射治疗同步用于脑转移瘤的症状性坏死
JAMA Oncol. 2023 Dec 1;9(12):1729-1733. doi: 10.1001/jamaoncol.2023.4492.
2
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.曲妥珠单抗衍生物治疗人表皮生长因子受体 2 表达转移性乳腺癌相关间质性肺病/肺炎的真实世界观点和实践。
JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
3
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.图卡替尼对比安慰剂，均联合曲妥珠单抗和卡培他滨，用于治疗先前接受过治疗的 ERBB2（HER2）阳性转移性乳腺癌且伴有脑转移的患者：HER2CLIMB 随机临床试验的更新探索性分析。
JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610.
4
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.九项曲妥珠单抗 deruxtecan 单药治疗研究中药物相关性间质性肺病和/或肺炎的汇总分析。
ESMO Open. 2022 Aug;7(4):100554. doi: 10.1016/j.esmoop.2022.100554. Epub 2022 Aug 11.
5
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
6
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、曲妥珠单抗和卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.
7
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.奥氮平用于预防化疗引起的恶心和呕吐。
N Engl J Med. 2016 Jul 14;375(2):134-42. doi: 10.1056/NEJMoa1515725.